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Flunisyn: Advanced 
Development of a Synthetic 








Whilst all reasonable care has been taken to ensure that this presentation is accurate and that the
forecasts, opinions and expectations contained in this presentation are fair and reasonable, this
presentation has not been independently verified and accordingly no representation or warranty,
expressed or implied, is made as to the accuracy, fairness or completeness of this presentation and no
reliance should be placed on the accuracy, fairness or completeness of this presentation. None of the
Company, the Company's employees, shareholders or any of their respective advisers accepts any
liability or responsibility for any loss howsoever arising, directly or indirectly, from any use of this
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presentation or its contents. Recipients of this presentation should conduct their own investigation,
evaluation and analysis of the Company.
London based biotech company developing vaccines for mutating viruses and cancer
Lead Program: Universal Flu vaccine (Flunisyn™)
• 2nd Phase-I study complete (Flunisyn +/- Adjuvant)  - Phase 2a initiation H2-2012
• Existing flu vaccines – poorly effective & don’t deliver T-cell correlates of protection
Pipeline extension offers unique targeted product profiles
Immune Targeting Systems
3
• Universal Hepatitis B therapeutic vaccine – targets antiviral treatment cessation (7MM/Asia)
• Cancer vaccine platform – Maximising immunogenicity whilst eliminating HLA screening
Investors:
Venture Fund
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Re-use capability (Booster effect) * Single vaccine regimen (Avoids heterologous prime-boost strategy)
Responder frequency High % respond to vaccination
(Eliminates HLA typing of human subjects)
Breadth of response Improved antiviral activity 
Mutating Viruses: Disease protection requires T-cell immunity





Magnitude & Quality of response Improved antiviral activity 
Broad cross reactive T-cell immunity All viral strains / genotypes


Historical T-cell vaccine pipeline failures highlight rate limiting immunological performance parameters
Improved vaccines must address full correlates of protection (unachieved by adjuvants alone) 
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DepoVaccine™ Promotes a Short Term Antigen Depot
DepoVaccines promote an antigen depot (↑ T1/2)
Depot forming adjuvant boosts immunogenicity 
Synthetic: Scalable, Stable & Characterisable 
C8F17 fluorocarbon chain
Densigen™
• 35aa conserved immunoprevalent antigen
• Non-envelop viral protein hydrophobic cores
DepoVaccine™ Antigen Delivery System
PB1/2, PA, NP & M1 
viral antigens1. Bioinformatics (in silico peptide 
selection)
Three step process:
Strain Species Period D Q V R E S R N P G N A E I E D L I F L A R S A L I L R G S V A H K S
Avian pre-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Human post-2000 . . . . . . . . . . . . . . . . . T . . . . . . . . . . . . . . . . .
Human pre-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Swine post-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Swine pre-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Avian post-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Human post-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Swine post-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Swine pre-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Avian pre-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Human post-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Human pre-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Avian pre-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Typical High Density Antigen Sequence Profile                                                
(35 amino Acid Reading Frame)
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Freeze Dried Nanoparticle Formulation
Flunisyn – contains 6 different Densigens2. Peptide Manufacture
3. Vaccine Formulation
Human post-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Human pre-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Swine pre-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Avian post-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Avian pre-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Human post-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Human pre-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Swine post-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M . . . .
Avian post-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Avian pre-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Avian post-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Avian pre-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Human post-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Human pre-2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
B40, B60, B61, A2    R E S R N P G N A                
B2702      S R N P G N A E I                     
B3701          G N A E I E D L I                
A0101, B3801, B58.1, A24, B35           N A E I E D L I F                
B40, B3701, B4403, B60, B61            A E I E D L I F L               
A0101, B7             E I E D L I F L A              
A24 D L I F L A R S A
           L I F L A R S A L          
              I F L A R S A L I         
B5301, B5401, A0201, B7, DR7, DR8                  F L A R S A L I L        
A3302, A3101, A24, DR3           L A R S A L I L R       
B5102, B5103, B5101, A24, B7                       S A L I L R G S V    
B8 A L I L R G S V A
A3, A1101                          I L R G S V A H K
H7N7
H9N2
A24, B8, DR1, DR7, DR11, DR13, DR15
Clustering of HLA Class I & II Binding Registers

















































































FlunisynTM: First Time in Human Study
Objective: Dose escalation study to establish initial data set with prototype formulation of 
Flunisyn (non-adjuvanted) – double blind and placebo controlled
1. Safety & immunogenicity (dose response)
2. Quality of immune response
a) T cell phenotype (cytokine expression, CD4/CD8)
b) X-reactivity to disparate influenza strains 
Study design:
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Group (n = 12 per cohort) Injections Blood samples
Placebo Day 1, 29 & 99 Day -7. 1, 8, 15, 29, 36, 53, 99, 106, 113, 279
Flunisyn (50µg/peptide) Day 1, 29 & 99 Day -7. 1, 8, 15, 29, 36, 53, 99, 106, 113, 279
Flunisyn (150µg/peptide) Day 1, 29 & 99 Day -7. 1, 8, 15, 29, 36, 53, 99, 106, 113, 279
Flunisyn (500µg/peptide) Day 1, 29 & 99 Day -7. 1, 8, 15, 29, 36, 53, 99, 106, 113, 279
Flunisyn™ Phase-I Clinical Summary 
Flunisyn is safe and well tolerated at all doses tested

















Increases in both CD4+ and CD8+ T cells post 
vaccination (day 36)
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Flunisyn boosts low levels of memory T-cells Flunisyn-specific T cell response (n=11) 








































n / 21 % %
HLA-A01 8 38% 52%
HLA-A02 11 52% 48%
HLA-A03 12 57% 45%






Flunisyn specific T-cells recognise cells infected 
with different influenza A virus strains
*
No difference in HLA-restriction between 
vaccine responders and overall HLA 
prevalence
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HLA-B07 14 67% 55%
HLA-B08 3 14% 24%
HLA-B27 4 19% 15%
HLA-B44 8 38% 42%
HLA-B58 3 14% 21%
HLA-B62 1 5% 6%
HLA-DR1 5 24% 24%
HLA-DR3 4 19% 24%
HLA-DR4 2 10% 12%
HLA-DR7 7 33% 30%
HLA-DR11 4 19% 15%
HLA-DR13 4 19% 15%
HLA-DR15 5 24% 21%













* Cross-reactivity correlated with degree of hepatoma cell line infectivity
*
*
Flunisyn™: Key Performance Parameters
Immunologically optimum dose – highlights its best-in-class potential:
 Responder frequency: 10/12 subjects met responder criteria (without HLA 
screening)
 Booster amplification: confirmed (at 1st & 2nd booster) 
 Breadth: mean 4.5 / 6 antigens (incl. multi-epitopic CD4 & 8 / antigen)
 Magnitude: significant increase over base line
 Cross reactivity: all potential seasonal & pandemic flu strains
9Summary Company DepoVaccine Platform                     Flunisyn™ HBV Oncology
Advax Significantly Enhances T-cell Immunogenicity (non Clinical)
4/6 Densigens
10 x 6/6 Densigens












Flunisyn + Advax impact on Inflexal
TIV (flu vaccine) HAI titres
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Advax (microparticulate Inulin) enhances Flunisyn & functional antibody responses to hemagglutinin 
(Rats)
 Magnitude of response (20X)
 Breadth of response (>50% include multi-epitopic / peptide responses)
 CD8 profile (30-40% of total response)
 Antiviral cytokines (500X)
Inflexal Inflexal + Flunisyn / AdjX
0
HAI 1:40 titres required for Regulatory approval
 HAI antibody titres (8X or 1:320)
Adds back missing T-cell correlates
• All potential influenza-A strains
• Annual prime vaccination 
Flunisyn™ MP-Inulin 
(Adjuvant)
Improved Influenza Disease Protection
Boosts antibody performance
• Improved HAI titres






Regulatory “Risk : Benefit” justification 
Lead indication: Improved Elderly seasonal flu vaccine – Flunisyn / MP-Inulin
Established seroprotection surrogate end-points are not correlated with clinical disease protection
• Clinical studies highlight T-cell immunity drives influenza disease protection
• Current seasonal flu vaccine does not deliver T-cell immunity
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+ TIV
Developing Unique Products and Platform
Flunisyn Programme:
• Start First in Elderly study Q2 2012
• Live virus challenge study H1 2013 
Universal Hepatitis B vaccine (Hepsyn) Programme:
• Pre-clinical GxP 2012/2013
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• Phase 1b H2 2013 
Oncology Programme:
• PoC Q3 2012
• Target selection Q3 2012
